Symbols

XLO

Xilio Therapeutics·NASDAQ

--(--)

XLO Profile

Xilio Therapeutics, Inc.

A biotech company that develops tumor-selective immuno-oncology therapies for cancer

Industry

Biological Technology

Established Date

06/18/2020

Listing Date

10/22/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.xiliotx.com

Security Type

Common stock

Office address

828 Winter Street Suite 300 Waltham MA 02451

Business

Introduction

Xilio Therapeutics, Inc., was incorporated in Delaware on June 18, 2020. The company is a clinical-stage biotechnology company that discovers and develops masking immunoecological (I-O) therapies designed to significantly improve outcomes for cancer patients. Leveraging its clinically validated masking technology and capabilities, the company is developing I-O therapies designed to be selectively activated in the tumor microenvironment to achieve long-lasting efficacy without the serious side effects associated with systemically active I-O drugs.